Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis

Ann Neurol. 2000 Jan;47(1):127-31.


We sought to determine whether combinations of glatiramer acetate and parenteral or ingested type I interferon were synergistic in experimental autoimmune encephalomyelitis. Glatiramer acetate, subcutaneous murine interferon-alpha, or ingested murine interferon-alpha individually improved clinical scores. In contrast, glatiramer acetate in conjunction with either subcutaneous or ingested interferon-alpha did not improve clinical scores compared with control. These data suggest that clinical trials designed to test a possible synergistic effect of glatiramer acetate and type I interferon in humans should be designed to detect possible adverse effects of this combination of immunomodulatory agents.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy*
  • Glatiramer Acetate
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use*
  • Interferon Type I / administration & dosage
  • Interferon Type I / therapeutic use*
  • Mice
  • Peptides / administration & dosage
  • Peptides / therapeutic use*


  • Immunosuppressive Agents
  • Interferon Type I
  • Peptides
  • Glatiramer Acetate